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Background: Aberrant neuroinflammation is suspected to contribute to the pathogenesis of myriad neurological
diseases. As such, determining the pathways that promote or inhibit glial activation is of interest. Activation of the
surface glycoprotein T-cell immunoglobulin and mucin-domain containing protein 3 (Tim-3) by the lectin galectin-9
has been implicated in promoting innate immune cell activation by potentiating or synergizing toll-like receptor
(TLR) signaling. In the present study we examined the role of the Tim-3/galectin-9 pathway in glial activation
in vitro.
Method: Primary monocultures of microglia or astrocytes, co-cultures containing microglia and astrocytes, and
mixed glial cultures consisting of microglia, astrocytes and oligodendrocytes were stimulated with poly(I:C) or LPS,
and galectin-9 up-regulation was determined. The effect of endogenous galectin-9 production on microglial
activation was examined using cultures from wild-type and Lgals9 null mice. The ability for recombinant galectin-9
to promote microglia activation was also assessed. Tim-3 expression on microglia and BV2 cells was examined by
qPCR and flow cytometry and its necessity in transducing the galectin-9 signal was determined using a Tim-3
specific neutralizing antibody or recombinant soluble Tim-3.
Result: Astrocytes potentiated TNF production from microglia following TLR stimulation. Poly(I:C) stimulation
increased galectin-9 expression in microglia and microglial-derived factors promoted galectin-9 up-regulation in
astrocytes. Astrocyte-derived galectin-9 in turn enhanced microglial TNF production. Similarly, recombinant
galectin-9 enhanced poly(I:C)-induced microglial TNF and IL-6 production. Inhibition of Tim-3 did not alter TNF
production in mixed glial cultures stimulated with poly(I:C).
Conclusion: Galectin-9 functions as an astrocyte-microglia communication signal and promotes cytokine
production from microglia in a Tim-3 independent manner. Activation of CNS galectin-9 likely modulates
neuroinflammatory processes in which TNF and IL-6 contribute to either pathology or reparation.
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Reactive gliosis is associated with many neurodegenerative
diseases and is considered a hallmark feature of neuroin-
flammatory diseases. It is well established that both micro-
glia and astrocytes express various toll-like receptors
(TLRs) [1], intracellular pathogen recognition receptors
[2,3], and danger signal receptors and are capable of
responding to their respective ligands, in part through the
production of chemokines, cytokines and growth factors
[4,5]. Given that dendritic cells are absent from the brain* Correspondence: jrli@cvm.tamu.edu
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article, unless otherwise stated.parenchyma and that the central nervous system (CNS) is
devoid of a draining lymphatic system, it is believed that
following infection of the CNS the initial recognition of
invading pathogens by resident glia is paramount in facili-
tating the attraction, stimulation, and regulation of both
the innate and adaptive arms of the peripheral immune
system within this organ [6,7]. Moreover, mounting evi-
dence suggests that inflammation in the CNS, which is or-
chestrated by reactive gliosis, ushers the reparation of
damaged tissues, much as occurs in the periphery [8,9].
Because some products, in particular proinflammatory
cytokines and reactive oxygen intermediates produced fol-
lowing glial activation, are potentially cytotoxic or resulttral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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of glial activation likely dictates the delicate balance
between the beneficial and detrimental effects of neuroin-
flammatory responses. In humans, aberrant glial activation
is associated with demyelinating diseases such as multiple
sclerosis [10] as well as a broad spectrum of other neuro-
logical diseases including stroke [11], epilepsy [12-14],
amyotrophic lateral sclerosis, Alzheimer’s and Parkinson’s
diseases [15] and depression [16,17]. Likewise, in an ani-
mal model of multiple sclerosis, experimental auto-
immune encephalomyelitis (EAE), microgliosis has been
shown to contribute to disease onset and progression
[18-20]. Furthermore, microglial production of the proin-
flammatory cytokines IL-6 and TNF appears to promote
the development of seizures following experimental infec-
tion of the CNS with Theiler’s murine encephalomyelitis
virus [21-25]. Acute glial activation following either per-
ipheral or central administration of low-dose lipopolysac-
charide (LPS) has been shown to induce symptoms of
depression in mice [26-28]. Therefore, uncovering the fac-
tors that regulate glial activation is pertinent to under-
standing CNS disease pathogenesis and the return to
homeostasis. Importantly, while much research has fo-
cused on the ability of either microglia or astrocytes to re-
spond to inflammatory stimuli, far fewer studies have
investigated potential intercellular pathways that are
exploited between glia to orchestrate inflammatory re-
sponses within the CNS.
Galectins are β-galactoside-binding proteins that exhibit
a broad range of functions, in part through their ability to
bind branched glycans on glycoconjugates causing lattice
formation and clustering of lipid rafts [29-31]. Recently,
galectins have gained increased recognition for their abil-
ity to influence immune responses, either by acting as
pathogen recognition receptors, modulating innate im-
mune responses or by regulating adaptive immunity [32].
However, the functional role of galectin expression, espe-
cially galectin-9, within the CNS is incompletely under-
stood. Studies in vitro have shown that galectin-9 can
induce maturation of human monocyte-derived dendritic
cells [33] and enhance proinflammatory cytokine secretion
[34], which have been attributable to its ability to bind the
highly glycosylated T-cell immunoglobulin and mucin
domain-containing protein 3 (Tim-3) [34]. While galectin-9
protein or the gene encoding galectin-9, Lgals9, is not nor-
mally expressed at high levels within the CNS [35,36], it is
increased following experimental pneumococcal meningitis
[37] as well as infection with herpes simplex virus [38] or
Japanese encephalitis virus [39] and is reportedly increased
in the brains of multiple sclerosis patients [34,40], indicat-
ing that it becomes up-regulated during inflammatory
conditions.
Herein, we report that astrocytes can promote micro-
glial TNF production. Notably, recombinant galectin-9potentiated both TNF and IL-6 secretion from microglia
when concurrently administered with poly(I:C). Add-
itionally, utilizing glia derived from Lgals9−/− mice we
found that galectin-9 was, in part, sufficient to elicit this
effect. Together, these results indicate that CNS-derived
galectin-9 can function as an interglial signaling mol-
ecule and may promote neuroinflammatory processes by
enhancing microglial TNF production.
Methods and materials
Animals
Rat glial cultures were obtained from Sprague Dawley rat
pups (P1-2; Harlan; Houston, TX, USA). Mouse cells were
from wild-type (C57BL/6 J; The Jackson Laboratory, Bar
Harbor, ME, USA), tlr4 mutant (tlr4−/−; The Jackson La-
boratory, Bar Harbor, ME, USA), Lgals9 mutant (Lgals9−/−)
and transgenic (Lgals9-EGFP) JF66Gsat/Mmucd mouse
pups (P1-2). Lgals9−/− mice were generated from heterozy-
gous breeding pairs originally obtained from the Consor-
tium of Functional Glycomics. Transgenic Lgals9:EGFP
mice (Lgals9-EGFP) JF66Gsat/Mmucd strain were reconsti-
tuted from MMRRC. The experimental procedures de-
scribed herein were approved by the Institutional Animal
Care and Use Committee and were performed in accord-
ance with guidelines of the National Institutes of Health.
Glial cultures
Primary microglia, astrocytes and mixed glial cultures
were isolated from the forebrains of Sprague Dawley rats
or mice as described previously [36,41-43]. Briefly,
brains were dissected and meninges removed, and the
tissue was digested with HBSS containing 0.01% trypsin
and 10 μg/ml DNase for 15 minutes at 37°C. The cells
were then washed with DMEM containing 10% heat-
inactivated FBS and 1% penicillin-streptomycin, filtered
through a sterile 70-μm filter, then plated onto poly-d-
lysine coated 75 cm2 flasks or directly into 24-well plates
for experiments using mixed glia. The medium was
changed every other day and cells were treated after
seven to eight days in vitro (DIV). For experiments in-
volving mono- and co-cultures, microglia were isolated
by shaking the mixed glia-containing flasks for 1 hour at
200 rpm. After removing microglia, the flasks were
shaken overnight to separate oligodendrocytes from the
astrocyte layer. The resulting astrocyte cultures were
treated with L-leucine methyl ester (1 mM) for 1 hour
before subculturing to remove additional contaminating
microglia. The purity of enriched monocultures was
consistently greater than 94%. Co-cultures of astrocytes
and microglia were reconstituted by plating microglia
directly onto enriched astrocytes. The BV2 microglial
cell line (a kind gift from Dr. Monica Carson, University
of California, Riverside) was cultured in complete
DMEM media consisting of DMEM supplemented with
Figure 1 Astrocytes enhance microglial TNF production after
poly(I:C) stimulation. (A) TNF levels from supernatants of mono- and
co-cultures of microglia and astrocytes following stimulation with
or without poly(I:C) (50 μg/ml) for 24 hours. Results are combined
means ± SE of seven independent experiments. (B) Synergistic effect of
astrocytes on microglial TNF is dependent on astrocyte number.
Microglia were added in increasing numbers to microglia or astrocyte
monocultures, and stimulated with poly(I:C) (50 μg/ml) for 24 hours
and TNF measured from the supernatants. Results are combined
means ± SE of three independent experiments. **P < 0.01, ***P < 0.001.
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sodium pyruvate (1 mM) (Sigma, St. Louis, MO, USA),
penicillin and streptomycin (100 U each; Life Technologies,
Carlsbad, CA, USA). Cells were treated with either poly
(I:C) (0 to 50 μg/ml) or LPS (0 to 100 ng/ml) (Sigma, St.
Louis, MO, USA) in DMEM medium supplemented with
0.1% BSA (Sigma, St. Louis, MO, USA) for 0 to 24 hours as
indicated in the figure legend.
Astrocyte dependent potentiation of microglial TNF
production
To determine the ability for astrocytes to promote
microglial TNF production, we first employed a limiting
dilution experiment. Here, microglia or astrocytes were
plated into poly-d-lysine coated 96-well plates at a dens-
ity of 5 × 104 cells per well. After 24 hours, increasing
numbers of newly isolated microglia were added to the
above established monocultures to achieve cell ratios of
0.0625:1, 0.25:1 and 1:1 as described in the Figure 1 le-
gend. The cells were then stimulated with poly(I:C)
(50 μg/ml) for 24 hours and TNF measured in the su-
pernatants by ELISA.
The necessity for living astrocytes to enhance TNF
production from microglia was examined by culturing
microglia (5 × 104) alone or with astrocytes (5 × 104)
that had either been previously fixed with ice-cold
methanol for 10 minutes or incubated with PBS and
washed extensively. The cultures were incubated over-
night at 37°C and then stimulated for 0, 4, 8 and 24 hours
with poly(I:C). TNF production was then determined by
ELISA.
To assess if the effect of astrocytes on microglia TNF
production was contact-dependent, we compared the
level of TNF production in microglia cultured with or
without physical contact with astrocytes using methods
described previously [41]. Briefly, 10 μl drops of Sylgard
(polydimethylsiloxane; Dow Corning Corp., Midland,
MI, USA) were spotted onto glass coverslips kept at low
heat on a hot plate (Corning Inc, Corning, NY, USA) to
create columns approximately 1 mm in height. The cov-
erslips were sterilized, coated with poly-d-lysine, washed
with sterile water and allowed to dry. Microglia were
plated onto these ‘bridged’ coverslips, which were flipped
over and placed into astrocyte cultures in 24-well plates
as indicated to create non-contacting microglia/astro-
cytes co-cultures. For co-cultures with direct physical
contacts between the two cell types, microglia were seeded
directly into the astrocyte cultures. The cells were stimu-
lated with poly(I:C) as described above for 24 hours.
Immunocytochemistry
Cells were grown on poly-d-lysine coated glass coverslips
in 24-well plates as described above. Following stimula-
tion, the cells were fixed with 4% paraformaldehyde for10 minutes at room temperature then washed with PBS.
The coverslips were then blocked and permeabilized with
PBS containing 0.1% Tween-20 (PBST) and 5% goat
serum for 1 hour at room temperature (RT) then incu-
bated with chicken anti-GFP (1/400; Life Technologies,
Carlsbad, CA, USA), rat anti-GFAP (1/200; Millipore,
Billerica, MA, USA) or rabbit anti-Iba-1 (1/2,000; Wako,
Richmond, VA, USA) overnight at 4°C in PBST. Subse-
quently, the coverslips were washed 3× with PBS then
incubated with fluorescently labeled goat anti-chicken,
anti-rat or anti-rabbit IgG (1/1,000; Life Technologies,
Carlsbad, CA, USA) for 1 hour in PBST containing 5%
goat serum. After washing, the coverslips were mounted
onto glass slides. Fluorescence intensity of GFP following
stimulation with poly(I:C) was determined as described
previously [44]. Images were captured using an Olympus
DP70 digital camera mounted on an Olympus IX71
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Japan). The background from each image was uniformly
subtracted using Photoshop then the mean fluorescence
intensity of each image was determined using ImageJ
(NIH) [44]. Expression data were generated from four in-
dependent mixed glial cultures. For each time-point the
mean fluorescence intensity of at least five random 10×
fields were averaged per culture per time point. To deter-
mine microglial cell number in mixed cultures, Iba-1+
cells in at least five random fields were counted using
ImageJ and averaged for each mouse. Averages from each
mouse were used for statistical analysis.
RNA isolation and RT-qPCR
RNA was extracted from cultured cells using Qiagen
RNeasy kits according the manufacturer’s instructions
(Qiagen, Valencia, CA, USA). Contaminating DNA was
removed by digestion with DNase I (Life Technologies,
Carlsbad, CA, USA). RNA was reverse transcribed using
a Promega AMV kit (Promega, Madison, WI, USA). To
test for residual DNA contamination, samples that were
reverse transcribed in the absence of reverse transcript-
ase were examined for amplification following PCR. For
non-quantitative RT-PCR, 100 ng cDNA was amplified
by PCR. For quantitative PCR, 10 ng of cDNA was used
for amplification. The specific primer pairs were used
for amplification: rat Gal-9, Forward-GGCATACCCCA
CCCCAGCCT, Reverse-CAGGCAGGCTTCGCTCCTC
G; rat GFAP, Forward-ACAAGGCGCTGGCAGCTGAG,
Reverse-CACGTGGACCTGCTGCTGGG; rat Iba-1, Forward-
CTTTTGGACTGCTGAAAGCC, Reverse-GTTTCTCCAGC
ATTCGCTTC; rat Tim-3, Forward-GTCCACATTGGAGTA
GGCGT, Reverse-TGAGTGCAGTCTCTGGGTTG; β-actin,
Forward-AGACTTCGAGCAGGAGATGG, Reverse-CCAT
CATGAAGTGTGACGTTG. For quantitative PCR, cDNA
was amplified using SYBR® according to the manufacturer’s
instructions (Life Technologies, Grand Island, NY, USA).
All samples were run in duplicate or triplicate. Gene
expression was normalized to β-actin and fold expres-
sion was calculated using the formula 2-ΔΔCt.
Western blot
The expression of galectin-9 and GFP in mixed glial cul-
tures following poly(I:C) stimulation was determined by
western blot as described previously with slight modifica-
tion [36,43]. Mixed glia were stimulated with poly(I:C)
(50 μg/ml; Sigma, St. Louis, MO, USA) for 24 hours, lysed
with Laemmli sample buffer, sonicated and frozen at −80°C
until use. The lysates were separated by SDS-PAGE, trans-
ferred to PVDF membranes, blocked for 1 hour at room
temperature and then incubated with goat anti-mouse Gal-
9 (1/1,000; R&D Systems, Minneapolis, MN, USA), chicken
anti-GFP (1/1,000; Life Technologies, Carlsbad, CA, USA)
or mouse anti-β-actin (1/8,000; Sigma, St. Louis, MO,USA) overnight at 4°C. After washing, the membranes
were incubated with horseradish peroxidase conjugated
anti-goat IgG (1/2,500; Jackson ImmunoResearch, West
Grove, PA, USA), anti-chicken IgY (1/5,000; Thermo Sci-
entific, Logan, UT, USA) or anti-mouse IgG (1/30,000;
Jackson ImmunoResearch, West Grove, PA, USA) for
1 hour at RT. Western blot were developed with Immun-
Star WesternC reagent (Bio-Rad; Hercules, CA, USA) and
images were acquired with a Bio-Rad Chemidoc XRS gel
documentation system (Bio-Rad; Hercules, CA, USA) and
quantified with Quantity One software (Bio-Rad;
Hercules, CA, USA).
Cytokine measurement from culture supernatants
Rat and mouse TNF was measured by ELISA according to
the manufacturer’s instructions (eBioscience; San Diego,
CA, USA). Mouse microglial TNF, IL-6, IL-1β, CCL2, IL-
12(p40) and IL-10 secretion following recombinant mouse
galectin-9 (2 μg/ml; R&D Systems, Minneapolis, MN,
USA) and poly(I:C) stimulation were measured by Lumi-
nex according to the manufacturer’s instructions (Bio-
Rad; Hercules, CA, USA).
Flow cytometry
All antibodies used for flow cytometry were from
eBioscience (San Diego, CA, USA). To determine Tim-3
surface expression, primary microglia or BV2 cells (1 ×
105) were suspended in 100 μl of flow cytometry buffer
(PBS containing 2% FBS), blocked with anti-CD16/32
(clone 93) for 10 minutes on ice, stained with anti-
CD11b-APC (clone M1/70), and anti-Tim-3-PE (clone
RMT3-23) or an isotype control (IgG2a) for 20 minutes.
To determine if exogenous galectin-9 could enhance
microglial expression of MHC II and CD86 following
poly(I:C) stimulation, cells (2 × 105) were plated onto
sterile 35-mm petri-dishes (Falcon; Becton Dickinson,
Franklin Lakes, NJ, USA) and treated with recombinant
galectin-9 (2 μg/ml) poly(I:C) (50 μg/ml), or both for
24 hours. The cells were detached with ice-cold Hanks’
Balanced Salt Solution (HBSS) containing 5 mM EDTA,
resuspended in flow cytometry buffer, blocked as de-
scribed above then stained with anti-MHC II-PE (I-A/I-
E; clone M5/114.15.2) or anti-CD86-PE (clone GL1) for
20 minutes on ice. Cells were gated on CD11b and the sur-
face expression of Tim-3, MHC II or CD86 was determined
by calculating mean fluorescence intensity using C6 Accuri
system software (BD Bioscience, San Jose, CA, USA).
Tim-3 inhibition
The contribution of Tim-3 in transducing the effects of
Gal-9 was determined using mixed glial cultures stimu-
lated with or without poly(I:C) in the presence of
increasing concentrations of either a neutralizing anti-
body to Tim-3 (clone 8B.2C12) or isotype control
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competitive ligation, mixed glial cultures were stimu-
lated with or without poly(I:C) in the presence of in-
creasing concentrations of soluble recombinant Tim-3
(Tim-3-Fc fusion protein). Levels of TNF in the super-
natant were then determined by ELISA. All reagents were
obtained from eBioscience (San Diego, CA, USA).Statistical analysis
All data are presented as means ± SE. To determine differ-
ences between experimental groups we employed two-
tailed Student's t-tests for comparisons between two
groups or analysis of variance (ANOVA) followed by
Bonferroni's post-hoc test to compare multiple groups. All
statistics were calculated using GraphPad Prism 4 (Graph-
Pad Software, San Diego, CA, USA). In all cases differ-
ences were considered significant when P < 0.05.Results
Astrocytes promote TNF production from microglia
Previously we found that microglia but not astrocytes se-
creted TNF following in vitro stimulation of mono- and
mixed glial cultures with either LPS or poly(I:C) [41,43].
Interestingly however, while astrocyte mono-cultures
failed to secrete TNF after either poly(I:C) or LPS stimu-
lation, they drastically enhanced microglial TNF produc-
tion when co-cultured with microglia (Figure 1A;
Additional file 1: Figure S1A). This synergistic increase
in cytokine production was dependent on the number of
astrocytes, but not microglia in the co-culture as in-
creasing the number of astrocytes cultured with micro-
glia recapitulated the effect while increasing the number
of microglia cultured with microglia failed to promote
additional TNF production past a certain threshold
(Figure 1B). The effect of astrocytes on microglia could
be attributable to their ability to promote microglial pro-
liferation and/or survival. However, immunocytochem-
ical analysis as well as the measurement of lactate
dehydrogenase release indicated that this was not the
case (Additional file 1: Figure S1B and C). To determine
if live astrocytes were necessary to enhance microglial
TNF production, we fixed astrocytes with methanol
prior to adding microglia (Additional file 2: Figure S2A).
As observed in previous experiments, control astrocytes
promoted TNF production from microglia following
poly(I:C) stimulation (Additional file 2: Figure S2B). In
contrast, astrocyte cultures that were fixed prior to
stimulation with poly(I:C) failed to promote TNF pro-
duction from microglia (Additional file 2: Figure S2A
and B). Furthermore, we determined that this effect was
contact dependent (Additional file 2: Figure S2C). To-
gether, these results demonstrate that active communi-
cation between the two cell types is required for theenhanced microglial TNF production observed in the
presence of astrocytes and indicate that an astrocyte-
derived factor(s) is likely involved in the synergy.
Stimulation of mixed glial cultures with the viral mimic
poly(I:C) increases galectin-9
Human and rodent astrocytes up-regulate galectin-9 fol-
lowing stimulation with various proinflammatory cyto-
kines, including IL-1β and TNF [36,45], both of which
are released from activated microglia. Furthermore, re-
combinant galectin-9 is reported to enhance innate
immune responses of dendritic cells [34] as well as pro-
motes dendritic cell maturation [33]. Therefore, we first
examined if poly(I:C) induces galectin-9 expression in
mixed glia. Stimulation of both rat (Figure 2A) and
mouse (Figure 2B) mixed glia with poly(I:C) resulted in
up-regulation of Lgals9 in a time-dependent fashion. Util-
izing mixed glia from galectin-9 EGFP mice (Lgals9:EGFP)
that contain EGFP expression cassette after galectin-9
promoter, we found that poly(I:C) time-dependently in-
creased galectin-9 expression as determined by increased
fluorescence intensity of GFP (Figure 2B) as well as
western blot analysis (Figure 2C). Similar responses
were observed following LPS stimulation (Additional
file 3: Figure S3A and B). In line with our previous re-
sults [36], microglia constitutively expressed Lgals9
(Figure 2B). However, in mixed glial cultures poly(I:C)
time-dependently induced EGFP expression in cells mor-
phologically resembled astrocytes (Figure 2D), a finding
that was further confirmed by immunocytochemical ana-
lysis, which revealed co-localization of GFP+ cells with
GFAP+ astrocytes (Figure 2E). Interestingly, microglia but
not astrocyte monocultures challenged with poly(I:C) or
LPS induced Lgals9 expression (Figure 2F; Additional
file 3: Figure S3C). As before [36], stimulation of astro-
cytes but not microglia monocultures with TNF induced
Lgals9 expression (Figure 2F), indicating that stimula-
tion of microglia with poly(I:C) up-regulates galectin-9
whereas microglial-derived cytokines such as TNF
causes galectin-9 up-regulation in astrocytes. Indeed,
conditioned media from poly(I:C) stimulated micro-
glia, but not media containing poly(I:C), increased
Lgals9 expression in astrocytes (Figure 2G). This effect
was abolished if the conditioned media was boiled prior to
its addition to astrocytes (Figure 2H), demonstrating that
the microglial factors that induce Lgals9 transcription are
heat sensitive.
Astrocyte-derived galectin-9 promotes microglial TNF
secretion
To determine if galectin-9 was responsible for the syner-
gic response from astrocytes, we stimulated control
(Lgals9+/+ or Lgals9+/−) and Lgals9−/− mixed glial cul-
tures with poly(I:C) and measured TNF secretion. There
Figure 2 Glia up-regulate galectin-9 following in vitro stimulation with poly(I:C). (A) Fold change in galectin-9 mRNA following stimulation
of rat mixed glia with vehicle control (PBS) or poly(I:C) (50 μg/ml) over time. Results are combined means ± SE from two independent experiments.
(B-E) Mouse mixed glia from Lgals9:EGFP mice (n = 4) stimulated with poly(I:C) (50 μg/ml). Time-dependent increase in both galectin-9 promoter
activation (B) and protein production (C) following stimulation. Galectin-9 localizes to both Iba-1+ microglia (D) and GFAP+ astrocytes (E). (F) Relative
Lgals9 expression in astrocyte (left) or microglia (right) monocultures following treatment with either recombinant TNF (5 ng/ml) or poly(I:C)
(50 μg/ml). Results are means ± SE of duplicate samples and are representative of three independent experiments. (G) (H) Conditioned media
from poly(I:C)-activated microglia is sufficient to induce Lgals9 expression in rat astrocyte cultures. Media obtained from microglia treated with
vehicle (PBS) or poly(I:C) (50 μg/ml) for 24 hours was used to treat astrocytes for 7 hours and Lgals9 up-regulation determined by RT-PCR (left).
Microglial conditioned media was heated to 100°C before adding to astrocytes (right). Results are representative of two to four independent experi-
ments. *P < 0.05, **P < 0.01, ***P < 0.001.
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cultures compared to Lgals9+/− cultures following poly(I:
C) stimulation (not shown). However, mixed glia derived
from Lgals9−/− mice produced approximately 35% less
TNF upon activation than control cultures (Figure 3A).
The number of microglial cells in these cultures did not
differ between genotypes (Figure 3B), thereby excluding
the possibility that the decrease in TNF production was
attributable to culture variation. Since microglia consti-
tutively express galectin-9 (Figure 2D and [36]), we
tested the possibility that a lack of microglial galectin-9
was responsible for the reduction in TNF. However, pri-
mary microglia isolated from Lgals9+/+ and Lgals9−/−
mice produced similar amounts of TNF after poly(I:C)
stimulation (Figure 3C). Likewise, production of TNF in
enriched astrocyte cultures, which is attributable to re-
sidual contaminating microglia [43] was similar between
genotypes (Figure 3C). To confirm that astrocyte-
derived galectin-9 was needed to synergize microgliaTNF production, we examined the effect of stimulation
on microglia alone or co-cultured with either Lgals9+/+
or Lgals9−/− astrocytes. Stimulation of microglia co-
cultured with Lgals9+/+ astrocytes produced more TNF
than either microglia alone or microglia co-cultured with
Lgals9−/− astrocytes, demonstrating that astrocyte-
derived galectin-9 promotes TNF production by micro-
glia (Figure 3D).
Recombinant galectin-9 is sufficient to promote
proinflammatory responses from microglia
Treatment of primary microglia with recombinant
galectin-9, poly(I:C), or both for 24 hours changed the cell
morphology (Figure 4A). To further characterize the ef-
fects of galectin-9 on the innate immune response from
microglia, we examined TNF, IL-6, IL-1β, CCL2, IL-10,
and IL-12(p40) secretion after poly(I:C) stimulation. Al-
though stimulation with exogenously added recombinant
galectin-9 appeared to increase the production of most
Figure 3 Astrocyte-derived galectin-9 promotes microglial TNF production. Mono-, co- or mixed glial cultures obtained from littermate
control (Lgals9+/+ or Lgals9+/−) or Lgals9−/− mice were stimulated with poly(I:C) (25 μg/ml) for 24 hours and TNF measured from the supernatants
by ELISA. (A-B) Reduction in supernatant levels of TNF obtained from mixed glia (A) despite similar numbers of Iba-1+ microglia across genotypes
(B). Results in (A) are combined means ± SE of 5 independent experiments (CTL n = 19; Lgals9−/− n = 12); results in (B) are combined means ± SE
of glial cultures depicted in (A) chosen at random (Lgals-9+/− n = 3; Lgals9−/− n = 3). Scale bar, 50 μm. (C) TNF levels from poly(I:C) activated
astrocyte and microglial monocultures derived from Lgals-9+/+ or Lgals9−/− mice. Results are means ± SE of quadruplicate samples and are
representative of two independent experiments. (D) Supernatant levels of TNF following poly(I:C) stimulation of microglial monocultures
compared to co-cultures containing Lgals-9+/+ (wild-type (WT); black) or Lgals9−/− (knockout (KO); red) astrocytes. Results are means ± SE of
quadruplicate samples and are representative of four independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
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significance (one-way ANOVA). In contrast, poly(I:C)
stimulation increased the secretion of all measured cyto-
kines (Figure 4B, C, D, E, F and G). Interestingly, micro-
glial TNF was significantly increased in poly(I:C) plus
galectin-9 treated cultures when compared to cultures
treated with only poly(I:C) (Figure 4B). While, galectin-9
co-treatment with poly(I:C) marginally enhanced IL-6
production when compared to poly(I:C) treatment alone,
the effect was not as robust as that observed for TNF
(Figure 4C). Importantly, the effects of recombinant
galectin-9 were unlikely to be attributable to residual
endotoxin resulting from the purification of recombinant
galectin-9 as the treatment of primary microglia derived
from Tlr4 null mice with galectin-9 also up-regulated
TNF (Additional file 4: Figure S4).
To test if galectin-9 alters the antigen presenting cap-
acity of microglia we cultured microglia in the presence of
galectin-9, poly(I:C), or both for 24 hours and analyzed
surface expression of MHC II and the co-stimulatorymolecule CD86 on CD11b+ gated cells by flow cytometry
(Figure 4H-J). While poly(I:C) up-regulated the surface ex-
pression of CD86 (Figure 4I) on microglia, recombinant
galectin-9 did not synergize this response. Collectively,
these data demonstrate the ability of exogenous galectin-9
to synergize poly(I:C) mediated TNF and to a lesser extent
IL-6 production in microglia.
Microglial Tim-3 expression does not account for the
effects of galectin-9
Galectin-9 has been shown to increase TNF production
from dendritic cells after LPS stimulation in a manner
dependent on Tim-3 [34]. As such, we questioned if the
effects of galectin-9 on microglia TNF production in
mixed glial cultures (Figure 3A) were mediated by Tim-
3 signaling. To begin, we first examined if Tim-3 was
expressed on microglia. Rat microglia but not astrocytes
constitutively expressed Havcr2 (the gene encoding
Tim-3) mRNA (Figure 5A). Similarly, flow cytometry
analysis of primary mouse microglia revealed low surface
Figure 4 Recombinant galectin-9 synergizes microglial TNF and IL-6 production. (A) Primary mouse microglia were unstimulated (CTL)
or stimulated with recombinant mouse galectin-9 (2 μg/ml), poly(I:C) (25 μg/ml), or galectin-9 and poly(I:C) together for 24 hours and cell
morphology examined by microscopy (A). (B-F) Following the above treatments chemokines and cytokines were simultaneously measured from
supernatants by Bioplex assay. Levels of TNF (B), IL-6 (C), IL-1β (D), IL-12(p40) (E), CCL2 (F) and IL-10 (G) are shown. Results are means ± SE of
triplicate samples and are representative of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001; †P < 0.05 versus control. (H-J)
Primary mouse microglia were stimulated as above for 24 hours, gated on CD11b (H) and the surface expression of CD86 (I) and MHC II (J)
determined by flow cytometry. Representative histograms (left) as well as combined mean fluorescence intensity values from three independent
experiments (right) are shown. Results are combined means ± SE of three independent experiments.
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http://www.jneuroinflammation.com/content/11/1/144expression levels of Tim-3, whereas the mouse microglia
cell line (BV2) exhibited much higher level of surface
Tim-3 (Figure 5B and C). Consistent with the low Tim-3
surface expression on microglia, poly(I:C) stimulation of
mixed glia in the presence of increasing concentrations
of a neutralizing antibody to Tim-3 (clone 8B.2C12) did
not suppress the amount of TNF produced whencompared to cultures co-treated with vehicle (PBS) or
an isotype control antibody (Figure 5D). Furthermore,
addition of excess soluble Tim-3 (Tim-3-Fc fusion pro-
tein) also failed to alter poly(I:C)-induced TNF secretion,
indicating that galectin-9 is not sequestered by Tim-3-Fc
or has a higher affinity/avidity for a different glycoconju-
gate through which it mediates its effects (Figure 5E).
Figure 5 Tim-3 is not required for the effects of galectin-9 on microglial cytokine production. (A) RNA was extracted from rat microglia or
astrocytes. Expression of Havcr3 (top), the microglia marker Iba-1 (middle), and the astrocyte marker Gfap (bottom) were examined by RT-PCR.
(B-C) Surface expression of Tim-3 was examined on CD11b+ primary mouse microglia (B; left) and BV2 cells (C; right) by flow cytometry. Results
are representative of three independent experiments for each cell type. (D-E) The effect of Tim-3 neutralization on TNF production in mouse
mixed glial cultures. (D) Cultures were stimulated with poly(I:C) for 24 hours in the presence of increasing concentrations of a neutralizing
antibody to Tim-3 (8B.2C12) or an isotype control (rat IgG1). (E) Cultures were stimulated with poly(I:C) and increasing concentrations of soluble
Tim-3. Results are means ± SE of duplicate samples and are representative of three independent experiments for each experiment. (F) Mouse BV2
cells were challenged with vehicle, LPS (100 ng/ml) or poly(I:C) (25 μg/ml) in the presence of increasing concentrations of recombinant mouse
galectin-9 (2 μg/ml) and TNF levels measured after 24 hours. Results are means ± SE of duplicate samples and are representative of two
independent experiments.
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Tim-3, stimulation of this BV2 microglial cell line with
recombinant galectin-9 did not increase TNF production
when concurrently administered with either poly(I:C) or
LPS (Figure 5F). Together these data strongly suggest
that galectin-9 is capable of acting in a Tim-3 independ-
ent fashion to promote TNF production from activated
microglia.
Discussion
In the current study we demonstrate that astrocytes en-
hance TNF production from activated microglia and that
this effect is primarily dependent on galectin-9. We
show that stimulation of glial cultures with the viral
mimic poly(I:C) or the Gram-negative bacterial product
LPS results in galectin-9 up-regulation in both microglia
and astrocytes via different signaling pathways. In line
with our finding that galectin-9 promotes microglial re-
sponses, we demonstrate that recombinant galectin-9
synergizes with poly(I:C) to increase TNF and IL-6 se-
cretion from cultured microglia. Finally, our data suggest
that the synergistic action of galectin-9 and poly(I:C) on
microglial TNF production is Tim-3 independent and
thus is likely to be transduced through an additional, yet
to be identified, glycoconjugate.
While galectin-9 is minimally expressed in the unchal-
lenged brain, its expression has been reported to increasefollowing acute infection with herpes simplex virus [46]
and during pneumococcal meningitis [37] indicating that
CNS infection likely promotes galectin-9 up-regulation.
Moreover, our current and previous data provide some evi-
dence regarding the mechanism of up-regulation for each
distinct cell type within the CNS following infection. Simi-
lar to that reported for human umbilical vein endothelial
cells [47], we found galectin-9 also is constitutively
expressed in cerebrovascular endothelial cells (Steelman
and Li personal observations). Additionally, we found
galectin-9 expression localized to quiescent resident micro-
glia in naïve animals (Steelman and Li personal observa-
tions), a finding that complements in vitro data from
previous experiments [36]. As in HUVEC [48,49] and mes-
enchymal stromal cells [50], we report here that galectin-9
expression can be induced in microglia following poly(I:C)
stimulation. However, despite astrocytes possessing poly(I:
C) receptors and being capable of producing CCL2/5 in re-
sponse to poly(I:C) stimulation [43], they themselves did
not directly up-regulate galectin-9 (Figure 2F) or produce
TNF [43] upon poly(I:C) stimulation. Moreover, astrocytes
neither bind to LPS nor express TLR4 [41,51,52] and did
not increase Lgals9 expression following LPS stimulation
(Additional file 3: Figure S3C). Together these findings may
suggest that epigenetic regulation of inflammatory genes
differ between microglia and astrocytes, a hypothesis that
has great implications but has yet to be thoroughly tested.
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in astrocytes is dependent on proinflammatory cytokines
from the surrounding milieu. The sufficiency of condi-
tioned media from poly(I:C) activated microglia to up-
regulate astroglial galectin-9 expression supports this hy-
pothesis. As such, following acute viral infection microglia
and endothelial cells are likely to increase galectin-9 directly
in response to pattern recognition receptor activation
whereas up-regulation in astrocytes depends on proinflam-
matory cytokines present in the surrounding tissue.
Understanding the physiological consequence of in-
creased galectin-9 expression within the CNS during en-
cephalitis brought on by central or peripheral infection
or autoimmunity is an important step towards under-
standing its therapeutic potential or pitfalls under vari-
ous causes of chronic neuroinflammation. At present
most previous studies have addressed the effects of
galectin-9 up-regulation with regard to its function on
adaptive immunity. Fewer studies have addressed the ef-
fects of galectin-9 on innate immunity with some con-
flicting results. For instance, it has been reported that
galectin-9 can promote innate immune responses from
antigen presenting cells [34] and that galectin-9 can pro-
mote dendritic cell maturation from monocyte-derived
macrophages [53]. Moreover, activation of Tim-3 by
galectin-9 is reported to aid in the clearance of myco-
bacterial tuberculosis which is mediated by increased IL-
1β release from monocytes [54,55]. However, siRNA me-
diated abolition of Tim-3 in monocytes has been shown
to cause increased production of IL-12(p70), an effect
that was attributable to the cis association of galectin-9
with Tim-3 [56,57].
To our knowledge, the current study represents the first
to demonstrate a role for galectin-9 in glial activation. Re-
cently, Lee and Goverman have investigated the role of
Tim-3 in antigen presenting cell function as it relates to
EAE [58]. In these experiments they demonstrated that
microglia isolated from both the quiescent and inflamed
CNS express Tim-3. However, microglial Tim-3 did not
alter the pathogenesis of EAE as bone marrow chimeric
mice generated from Tim-3 null mice reconstituted with
wild-type bone marrow did not differ in disease severity
when compared to controls [58]. Furthermore, they did
not find evidence to support a role for Tim-3 in modulat-
ing proinflammatory cytokine release or antigen present-
ing cell function from isolated dendritic cells [58]. In line
with these data, the results from the current study suggest
that galectin-9 can promote inflammatory cytokine pro-
duction, but does so in a manner that is not, to say the
least, entirely dependent on Tim-3 signaling. Some of
these seemingly conflicting results may be partially
explained by the promiscuous nature of galectin-
glycoprotein interactions. As galectins have an affinity for
specific glycan moieties on glycoconjugates they would beexpected to have multiple binding partners. Indeed, in
addition to Tim-3 [59] galectin-9 has also been shown to
bind CD40 [60], CD44 [61,62], protein disulfide isomerase
[62], ICAM3, PECAM1, Integrin β1, Integrin β2, Integrin
αL, CD2, CD6, CD26, CD45, CD48, CD107a, and CD148
[61]. Finally, the glycosylation status of proteins greatly in-
fluences galectin avidity [30,63]. Therefore, variation ex-
perimental culture conditions could potentially account
for some discrepancies.
Conclusion
We have demonstrated that astrocyte-derived galectin-9
potentiates TNF and to a lesser extent IL-6 production
from microglia in vitro in a Tim-3 independent manner.
Galectin-9 expression is increased in microglia following
TLR ligation. However, its expression in astrocytes is likely
dependent on microglia-derived cytokine production, at
least in vitro. Initially, this physiological response may
function to promote pathogen clearance from the CNS.
However, the pathophysiological outcome of galectin-9
up-regulation within the CNS is incompletely understood.
Whether glia-derived galectin-9 promotes or suppresses
neuroinflammatory diseases is currently the subject of on-
going investigation.
Additional files
Additional file 1: Figure S1. Enhanced TNF production in microglia/
astrocyte co-cultures is observed following LPS stimulation. (A) TNF levels
from supernatants of mono- and co-cultures of astrocytes and microglia
following stimulation with or without LPS (100 ng/ml) for 24 hours.
Results are combined means ± SE of three independent experiments. (B)
The number of microglia in each condition was determined by counting
Iba-1+ cells in cultured treated with or without poly(I:C) (50 μg/ml) for
24 hours. The results are mean ± SE of 5 to 7 20x fields from a single
experiment and are representative of 2 independent experiments.
**P < 0.01, ***P < 0.001. (C) Lactate dehydrogenase (LDH) levels in culture
supernatants from experiment (B).
Additional file 2: Figure S2. Live astrocytes promote microglia TNF
production in a contact-dependent manner. (A) Schematic illustration of
the experimental design in (B). Astrocytes were plated at 5 × 104 cells per
well in a 96-well plate. After 22 hours the cells were incubated with either
PBS (left) or ice-cold methanol (right) for 10 minutes at RT. After washing
twice with warm media, 5 × 104 microglia were added to each well. The
following day the cells were treated with poly(I:C) (50 μg/ml) for 0, 4, 8
and 24 hours. (B) ELISA results showing TNF secretion from microglia
monocultures, microglia co-cultured with live astrocytes, microglia
co-cultured with methanol-fixed astrocytes, or astrocyte monocultures
following poly(I:C) stimulation. Results are means ± SE from triplicate
wells. (C) Schematic illustration of the no-contact experimental design
whereby microglia and astrocytes were cultured together but physically
separated. The illustration is a reproduction from a similar illustration
published previously [41]. (D) TNF production from microglia cultured
alone or in the presence of astrocytes with (black bars) or without (white
bars) contact following poly(I:C) (50 μg/ml) for 24 hours. Results are
means ± SE from triplicate measurements of two separate wells per
condition and are representative of three independent experiments.
**P < 0.01, ***P < 0.001.
Additional file 3: Figure S3. LPS up-regulates galectin-9. (A and B)
Mixed glia from Lgals9:EGFP mice were stimulated with LPS (100 ng/ml)
and time-dependent increase in galectin-9 promoter activation was
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http://www.jneuroinflammation.com/content/11/1/144evaluated. (B) is the mean fluorescence intensity from duplicates over time.
Scale bar, 100 μm. (C) The effect of TNF (5 ng/ml) and LPS (100 ng/ml) on
Lgals9 expression in rat astrocytes (left) or microglia (right) monocultures as
determined by RT-qPCR. Results are means ± SE of triplicate samples and
are representative of two independent experiments.
Additional file 4: Figure S4. The effects of galectin-9 are not attributable
to residual endotoxin. Microglia were isolated from wild-type C57BL/6 mice
(WT) or toll-like receptor mutant mice (Tlr4−/−) and plated into 96-well plates
at 5 × 104 cells per well. Microglia from WT (left) or Tlr4−/− (right) mice were
treated with or without recombinant galectin-9 (2 μg/ml) for 24 hours and
TNF levels determined.
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